Skip to main content

Table 5 Sensitivity analyses adjusted for pharmacological treatment in rheumatoid arthritis patients included 1 January 2006 and later a

From: The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study

Risk window TNFi-exposed RA patients ACS/person-years (N = 4,385) Biologic-naïve RA patients ACS/person-years (N = 13,155) General population comparator ACS/person-years (N = 21,925) TNFi-exposed vs. biologic-naïve RA patients TNFi-exposed RA patients vs. general population comparator HR b(95% CI) Biologic-naïve RA patients vs. general population comparator HR b(95% CI)
HR b(95% CI) HR c(95% CI)
Ever exposed to TNFi 46/10,116 163/26,398 162/50,692 0.77 (0.55 to 1.07) 0.72 (0.51 to 1.02) 1.45 (1.05 to 2.02) 1.83 (1.47 to 2.27)
Actively on TNFi 31/8,427 132/21,928 128/41,757 0.64 (0.43 to 0.95) 0.64 (0.43 to 0.96) 1.21 (0.82 to 1.79) 1.85 (1.45 to 2.36)
Short-term exposure 22/5,986 107/18,229 102/33,574 0.69 (0.44 to 1.09) 0.64 (0.40 to 1.03) 1.27 (0.80 to 2.02) 1.83 (1.39 to 2.40)
  1. aACS, Acute coronary syndrome; HR, Hazard ratio; RA, Rheumatoid arthritis; TNFi, Tumour necrosis factor inhibitor. bAdjusted for age, sex and county of residence. cAdjusted for sex; age; county of residence; year of inclusion; diabetes mellitus (treatment and/or previous diagnosis); hypertension (treatment and/or previous diagnosis); previous diagnosis of chronic obstructive pulmonary disease, cerebrovascular disease or other atherosclerotic disease; previous hospitalization for infection; total number of days in hospital during 10 years prior to inclusion; RA disease duration more than 10 years; sick leave; disability pension; previous joint surgery; education level; and dispensed pharmacological treatment within 6 months prior to inclusion (acetylsalicylic acid, corticosteroids, disease-modifying antirheumatic drugs, lipid-lowering drugs, nonsteroidal anti-inflammatory drugs and coxibs). The frequency of the covariates in the RA cohorts is reported in Additional file 2.